The immunohistochemistry of CRC tissue with the KRAS mutation showed expression of CD44 and CD166, cancer stem cell markers that are responsible for tumor cell transformation, growth, and proliferation with a higher risk of lymph node involvement by the tumor and the development of liver and lung metastasis [44]. The gene discussed is KRAS; the disease is neoplasm.